Home
January 2010 February 2010 March 2010
Su Mo Tu We Th Fr Sa
Week 5 1 2 3 4 5 6
Week 6 7 8 9 10 11 12 13
Week 7 14 15 16 17 18 19 20
Week 8 21 22 23 24 25 26 27
Week 9 28
Reach urologists

Current Management of Erectile Dysfunction After Cancer Treatment - Abstract Show Comments PDF Print E-mail
  
Monday, 13 July 2009

Department of Urology, Institut Jules Bordet, Brussels, Belgium.

This email address is being protected from spam bots, you need Javascript enabled to view it

Erectile dysfunction has a major impact on quality of life. Treating sexual dysfunction after cancer treatment requires special concern because of specific medical, psychological and social factors. This article presents the relevant experimental and clinical recent literature on rehabilitation of erectile function after surgery, external beam radiotherapy, brachytherapy or hormonal deprivation therapy for prostate cancer as it is the most studied model for erectile dysfunction management.

Counseling and reeducation with a multidisciplinary approach seems to be both mandatory and effective in achieving erectile function recovery. Administration of proerectile drugs nightly or on-demand early after cancer treatment is probably the key factor of erectile rehabilitation. Several studies have highlighted the presumption of a potential role for phosphodiesterase type 5 inhibitors (PDE5-Is) in the prevention of endothelial damage related to ischemia-reperfusion and denervation following surgery or pelvic radiation. Larger multicancer, randomized, controlled trials are needed to assess the role of PDE5-Is in erectile dysfunction pharmacological prophylaxis and rehabilitation strategy.

Erectile dysfunction postcancer treatment requires multimodal management with early administration of PDE5-Is, combined therapy to maintain erectile tissue oxygenation if necessary with PDE5-Is, intracavernosal injection and transurethral alprostadil or even vacuum erect device, psychological counseling considering erectile dysfunction as a couple's issue. The best modality to optimize postcancer erectile dysfunction management has not yet been standardized and is still challenging.

Written by:
Peltier A, van Velthoven R, Roumeguère T.   Are you the author?

Reference:
Curr Opin Oncol. 2009 Jul;21(4):303-9.
doi:10.1097/CCO.0b013e32832b9d76

PubMed Abstract
PMID:19509501

UroToday.com Erectile Dysfunction (ED) Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 2
PoorBest


 
Visitor Ratings:
Patients:
4 (1 votes)

No Affiliation:
5 (1 votes)


Bookmark and Share

Member's Section

Login

Sign Up

Quick Search

Meet the Expert


All Experts



Featured Conference

Media and Publisher

Advertising Rates

Working with Industry

Case Studies
Sponsorship Opportunities

Erectile Dysfunction
Sponsored By